Nafamostat has anti-asthmatic effects associated with suppressed pro-inflammatory gene expression, eosinophil infiltration and airway hyperreactivity (1)
Nafamostat is currently employed clinically for treating pancreatitis. However, its potential as a therapeutic agent has extended beyond pancreatitis to various other inflammatory conditions. Nafamostat mesylate, a synthetic inhibitor, exhibits the capacity to inhibit multiple types of serine proteases, with a specific affinity for mast cell tryptase. Consequently, researchers explored the therapeutic possibilities of nafamostat in a mouse asthma model utilizing house dust mites (HDM).
One of the markers in this study was the levels of serum HDM-specific IgE antibodies, determined using Chondrex, Inc.’s ELISA kit (Cat# 3027) within their mouse models sensitized to HDM allergens.
The results of this investigation demonstrated that nafamostat effectively mitigates several fundamental features of asthma, including the suppression of gene expression patterns typically associated with inflammatory responses.
